An update on the use of antifungal agents;Atualização no uso de agentes antifúngicos

Jornal Brasileiro de Pneumologia

Volumn 32, Issue 5, 2006, Pages 449-460

  Martinez, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphotericin b administration dosage; Antifungal agents drug therapy; Aspergillosis; Combination; Drug therapy; Fungal drug therapy; Lung diseases

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPEPTIDE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

HUMAN; LUNG MYCOSIS; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; HUMANS; LUNG DISEASES, FUNGAL; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 33846884232     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/S1806-37132006001300013     Document Type: Review

References (81)

1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308-29.
2. Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152(5):1037-43.
3. Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis. 1998;26(2):334-8.
4. Comment in: Clin Infect Dis. 1998;26(2):339-40.
5. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJA. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23(4):279-91.
6. Martinez R, Castro G, Moya MJ, Quaglio AS, Figueiredo JFC, Machado AA, et al. Anfotericina B lipídica como terapia seqüencial da anfotericina B convencional: redução da toxicidade sem perda da eficácia. Rev Soc Bras Med Trop. 1998;31(S1):127-7.
7. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998;42(6):1412-6.
8. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother. 1991;35(4):615-21.
9. Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother. 1992;36(12):2656-60.
10. Pahls S, Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis. 1994;169(5):1057-61.
11. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37(3):415-25.
12. Comment in: Clin Infect Dis. 2004;38(2):303-4; author reply 306-7.
13. Clin Infect Dis. 2004;38(2):303; author reply 306-7.
14. Clin Infect Dis. 2004;38(2):304-5; author reply 306-7.
15. Clin Infect Dis. 2004;38(2):305-6; author reply 306-7.
16. Nucci M, Loureiro M, Silveira F, Casali AR, Bouzas LF, Velasco E, et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother. 1999;43(6):1445-8.
17. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27(6):1406-12.
18. Comment in: Clin Infect Dis. 1998;27(6):1413-4.
19. Gavalda J, Martin T, Lopez P, Gomis X, Ramirez JL, Rodriguez D, et al. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis. Clin Microbiol Infect. 2005;11(12):999-1004.
20. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991;28 Suppl B:73-82.
21. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711-8.
22. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340(10):764-71.
23. Leenders AC, Reiss P, Portegies P, Clezy K, Hop NC, Hoy J, et al. Liposomal amphoterin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococal meningitidis. AIDS. 1997;11(12):1463-71.
24. Tollemar J, Ringdén O. Early pharmacokinetic and clinical results from a noncomparative multicenter trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome). Drug Investig. 1992;4:232-8.
25. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol. 1994;86(4):754-60.
26. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med. 1995;155(10):1093-8.
27. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991;35(6):1208-13.
28. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27(2):296-302.
29. Comment in: Clin Infect Dis. 1999;28(4):935-6.
30. Clin Infect Dis. 2000;30(1):236-7.
31. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35(4):359-66.
32. Comment in: Clin Infect Dis. 2002;35(4):367-9.
33. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis. 1995;21(5):1145-53.
34. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis. 1996;173(5):1208-15.
35. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22(2):315-21.
36. Comment in: Clin Infect Dis. 1996;22(2):329-30.
37. Mehta J, Chu P, Powles R, Kelsey S. Amphotericin B lipid complex for the treatment of presumed or confirmed fungal infections in immunocompromised patients with hematologic malignancies. Drugs Today. 1996;32:417-21.
38. Merhav H, Mieles L. Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplant Proc. 1997;29(6):2670-4.
39. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383-96.
40. Comment in: Clin Infect Dis. 2000;30(1):236-7.
41. Tavares W. Azóis antifúngicos. In. Tavares W, editor. Manual de antibióticos e quimioterápicos antiinfecciosos. São Paulo: Atheneu; 2001. p. 869-86.
42. Diakema DJ, Messer AS, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41(8):3623-6.
43. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630-7.
44. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546-53.
45. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.
46. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563-71.
47. Comment in: Clin Infect Dis. 2002;35(10):1273-5.
48. Pedroche CD, Cisneros JM, Lumbreras C, Aguado JM. Tratamiento con voriconazol de las infecciones fúngicas invasoras. Evaluación de la experiencia del uso compasivo de voriconazol en España. Rev Esp Quimioterap. 2005; 18:149-58.
49. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435-42.
50. Comment in: Lancet. 2005;366(9495):1413-4.
51. Lancet. 2006;367(9512):728-9; author reply 729.
52. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225-34.
53. Perfect JR, Marr KA, Walsh T, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122-31.
54. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36(11):1445-57.
55. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950-6.
56. Arathoon E, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2002;46(2):451-7.
57. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113(4):294-9.
58. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-9.
59. Comment in: ACP J Club. 2003;139(1):15.
60. N Engl J Med. 2002;347(25):2070-2.
61. N Engl J Med. 2003;348(13):1287-8; author reply 1287-8.
62. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563-71.
63. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004; ;351(14):1391-402.
64. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE; U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105-9.
65. Summary for patients in: Ann Intern Med. 2002;137(2):I54.
66. Summary for patients in: Ann Intern Med. 2002;137(2):I54.
67. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27(3):603-18.
68. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis. 2002;35(7):891-5.
69. Comment on: Clin Infect Dis. 2002;34(6):730-51.
70. Clin Infect Dis. 2002;35(7):896-7; author reply 897-8.
71. Martinez R, Malta MHB, Verceze AV, Arantes M, Vitali LH. Avaliação do complexo lipídico de anfotericina B (ABLC) no tratamento da paracoccidioidomicose experimental. Rev Soc Bras Med Trop. 2002;35(Supl 1):183-3.
72. Dietze R, Fowler VG Jr, Steiner TS, Pecanha PM, Corey GR. Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis. Am J Trop Med Hyg. 1999;60(5):837-9.
73. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy. 2004;24(2 Pt 2):4S-28S; quiz 29S-32S.
74. Klatersky J. Empirical antifungal therapy. Int J Antimicrob Agents. 2004; 23(2):105-12.
75. Telles FQ, Goldani Telles FQ, Goldani LZ, Goodrich JM, Schlamm HT, Shikanai-Yasuda MA. An open-label comparison of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Rev Inst Med Trop S Paulo. 2005; 47 (Suppl.14):40-9.
76. Wheat J, Sarosi G, Mckinsey D, Hamill R, Bradsher R, Johnson P et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis. 2000; 30: 688-95.
77. Steinbach WJ, Stevens DA. Review of never antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003; 37(Suppl 3): S 157-87.
78. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000;30:710-8.
79. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004; 38:161-89.
80. Hospenthal DR. Uncommon fungi. In. Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2005. p. 3068-79.
81. Patterson TF. Combination antifungal therapy. Ped Infect Dis J. 2003; 22:555-6.